[{"id":"c72fcab2-47e2-44ff-b31e-46bbe6c6905c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01305213","created_at":"2021-01-18T05:18:32.660Z","updated_at":"2024-07-02T16:36:57.567Z","phase":"Phase 2","brief_title":"Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT01305213","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • Zybrestat (fosbretabulin)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 03/21/2011","start_date":" 03/21/2011","primary_txt":" Primary completion: 08/20/2016","primary_completion_date":" 08/20/2016","study_txt":" Completion: 11/03/2016","study_completion_date":" 11/03/2016","last_update_posted":"2019-07-30"},{"id":"37e7ef56-b650-4b32-a176-09f449bac0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02132468","created_at":"2021-01-18T09:53:32.107Z","updated_at":"2024-07-02T16:37:15.827Z","phase":"Phase 2","brief_title":"A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers","source_id_and_acronym":"NCT02132468","lead_sponsor":"Mateon Therapeutics","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zybrestat (fosbretabulin)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2017-12-05"}]